234 related articles for article (PubMed ID: 31025148)
1. ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.
Vacarean-Trandafir IC; Ivanov IC; Dragos LM; Dascalescu AS; Titieanu AA; Cojocaru D
Mol Biol Rep; 2019 Aug; 46(4):3747-3754. PubMed ID: 31025148
[TBL] [Abstract][Full Text] [Related]
2. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
3. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
4. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
[TBL] [Abstract][Full Text] [Related]
6. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
7. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
12. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
14. ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
Shojaei M; Rezvani H; Azarkeivan A; Poopak B
Lab Med; 2021 Mar; 52(2):158-167. PubMed ID: 32821940
[TBL] [Abstract][Full Text] [Related]
15. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA
Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
Martínez-Castillo M; Gómez-Romero L; Tovar H; Olarte-Carrillo I; García-Laguna A; Barranco-Lampón G; De la Cruz-Rosas A; Martínez-Tovar A; Hernández-Zavala A; Córdova EJ
Leuk Res; 2023 Aug; 131():107325. PubMed ID: 37302352
[TBL] [Abstract][Full Text] [Related]
18. A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
Marcé S; Cortés M; Zamora L; Cabezón M; Grau J; Millá F; Feliu E
Exp Mol Pathol; 2015 Aug; 99(1):16-8. PubMed ID: 25913326
[TBL] [Abstract][Full Text] [Related]
19. Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
Strhakova L; Bujalkova MG; Hojsikova I; Lukackova R; Behulova R; Mistrik M; Repiska V
Neoplasma; 2011; 58(6):548-53. PubMed ID: 21895409
[TBL] [Abstract][Full Text] [Related]
20. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M; Soverini S; De Benedittis C
Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
